AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
This trial used a multicentre, single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel. Patients included in this trial were advanced breast cancer with hormone receptor negative and Her2 negative. The primary endpoint is ORR, and the secondary endpoint is DCR, PFS, OS and safety.
Breast Neoplasm Female
DRUG: AK105|DRUG: Anlotinib hydrochloride|DRUG: Albumin Paclitaxel
Overall Response Rate (ORR), Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1., Up to approximately 10 months
Disease Control Rate (DCR), DCR: Disease Control Rate, defined as the proportion of patients with the best overall response of complete response (CR) , partial response (PR) or stable disease (SD) according to RECIST 1.1., Up to approximately 10 months|Progression Free Survival (PFS), PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause., Up to approximately 10 months|Overall Survival (OS), OS: Time from date of randomization to the date of death from any cause., Up to approximately 18 months
This trial used a multicentre, single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel. Patients included in this trial were advanced breast cancer with hormone receptor negative and Her2 negative. The primary endpoint is ORR, and the secondary endpoint is DCR, PFS, OS and safety.